Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

Head and Neck

Volumn 38, Issue 4, 2016, Pages 620-627

  Dillon, Patrick M ^a   Chakraborty, Samhita ^b   Moskaluk, Christopher A ^c   Joshi, Prashant J ^a   Thomas, Christopher Y ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

adenoid cystic carcinoma; MYB gene; NFIB gene; nuclear factor I B; salivary gland; tyrosine kinase inhibitor

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AXITINIB; BORTEZOMIB; CETUXIMAB; CISPLATIN; DASATINIB; DOVITINIB; DOXORUBICIN; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; NELFINAVIR; PROTEIN MYB; SUNITINIB; VORINOSTAT;

ADENOID CYSTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG TARGETING; GENE FUSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; CARCINOMA, ADENOID CYSTIC; CHROMOSOME 6; CHROMOSOME 9; FEMALE; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETICS; MALE; MUTATION; ONCOGENE MYB; PATHOLOGY; PROCEDURES; SALIVARY GLAND NEOPLASMS;

CARCINOMA, ADENOID CYSTIC; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 9; CLINICAL TRIALS AS TOPIC; FEMALE; GENES, MYB; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; SALIVARY GLAND NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84930989468     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23925     Document Type: Review

References (82)

1. Chummun S, McLean NR, Kelly CG, et al., Adenoid cystic carcinoma of the head and neck. Br J Plast Surg 2001; 54: 476-480.
2. Spiro RH, Huvos AG, Strong EW,. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 1974; 128: 512-520.
3. Papaspyrou G, Hoch S, Rinaldo A, et al., Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A review. Head Neck 2011; 33: 905-911.
4. Spiro RH, Huvos AG,. Stage means more than grade in adenoid cystic carcinoma. Am J Surg 1992; 164: 623-628.
5. Khan AJ, DiGiovanna MP, Ross DA, et al., Adenoid cystic carcinoma: A retrospective clinical review. Int J Cancer 2001; 96: 149-158.
6. Li N, Xu L, Zhao H, El-Naggar AK, Sturgis EM,. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. Cancer 2012; 118: 3945-3953.
7. Jaso J, Malhotra R,. Adenoid cystic carcinoma. Arch Pathol Lab Med 2011; 135: 511-515.
8. Azumi N, Battifora H,. The cellular composition of adenoid cystic carcinoma. An immunohistochemical study. Cancer 1987; 60: 1589-1598.
9. Caselitz J, Schulze I, Seifert G,. Adenoid cystic carcinoma of the salivary glands: An immunohistochemical study. J Oral Pathol 1986; 15: 308-318.
10. Chen W, Dong S, Zhou J, Sun M,. Investigation of myoepithelial cell differentiation into Schwann-like cells in salivary adenoid cystic carcinoma associated with perineural invasion. Mol Med Rep 2012; 6: 755-759.
11. Prasad AR, Savera AT, Gown AM, Zarbo RJ,. The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med 1999; 123: 801-806.
12. Moskaluk CA,. Adenoid cystic carcinoma: Clinical and molecular features. Head Neck Pathol 2013; 7: 17-22.
13. Andreadis D, Epivatianos A, Poulopoulos A, et al., Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol 2006; 42: 57-65.
14. Vila L, Liu H, Al-Quran SZ, Coco DP, Dong HJ, Liu C,. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol 2009; 22: 1296-1302.
15. Jiang LC, Huang SY, Zhang DS, et al., Expression of beclin 1 in primary salivary adenoid cystic carcinoma and its relation to Bcl-2 and p53 and prognosis. Braz J Med Biol Res 2014; 47: 252-258.
16. Moskaluk CA, Baras AS, Mancuso SA, et al., Development and characterization of xenograft model systems for adenoid cystic carcinoma. Lab Invest 2011; 91: 1480-1490.
17. Frierson HF Jr, El-Naggar AK, Welsh JB, et al., Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 2002; 161: 1315-1323.
18. Dong C, Wilhelm D, Koopman P,. Sox genes and cancer. Cytogenet Genome Res 2004; 105: 442-447.
19. Daa T, Kashima K, Kaku N, Suzuki M, Yokoyama S,. Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol 2004; 17: 1475-1482.
20. Edwards PC, Bhuiya T, Kelsch RD,. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 586-593.
21. Ito FA, Ito K, Coletta RD, Graner E, de Almeida OP, Lopes MA,. Salivary gland tumors: Immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67. Anal Quant Cytol Histol 2009; 31: 280-287.
22. Myoken Y, Myoken Y, Okamoto T, et al., Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours. J Pathol 1996; 178: 429-436.
23. Rao PH, Roberts D, Zhao YJ, et al., Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res 2008; 14: 5181-5187.
24. Ho AS, Kannan K, Roy DM, et al., The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013; 45: 791-798.
25. Stephens R, Mythen M, Kallis P, Davies DW, Egner W, Rickards A,. Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter. Br J Anaesth 2001; 87: 306-308.
26. Zhang J, Peng B, Chen X,. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: Correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11: 7334-7343.
27. Persson F, Fehr A, Sundelin K, Schulte B, Löning T, Stenman G,. Studies of genomic imbalances and the MYB-NFIB gene fusion in polymorphous low-grade adenocarcinoma of the head and neck. Int J Oncol 2012; 40: 80-84.
28. Persson M, Andrén Y, Moskaluk CA, et al., Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 2012; 51: 805-817.
29. Hudson JB, Collins BT,. MYB gene abnormalities t(6;9) in adenoid cystic carcinoma fine-needle aspiration biopsy using fluorescence in situ hybridization. Arch Pathol Lab Med 2014; 138: 403-409.
30. Pusztaszeri MP, Sadow PM, Ushiku A, Bordignon P, McKee TA, Faquin WC,. MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens. Cancer Cytopathol 2014; 122: 257-265.
31. Brill LB II, Kanner WA, Fehr A, et al., Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 2011; 24: 1169-1176.
32. Mitani Y, Li J, Rao PH, et al., Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res 2010; 16: 4722-4731.
33. Stenman G, Andersson MK, Andrén Y,. New tricks from an old oncogene: Gene fusion and copy number alterations of MYB in human cancer. Cell Cycle 2010; 9: 2986-2995.
34. Frierson HF Jr, Moskaluk CA,. Mutation signature of adenoid cystic carcinoma: Evidence for transcriptional and epigenetic reprogramming. J Clin Invest 2013; 123: 2783-2785.
35. Ross JS, Ali SM, Wang K, et al., Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 2013; 130: 554-559.
36. Bell D, Hanna EY, Miele L, Roberts D, Weber RS, El-Naggar AK,. Expression and significance of notch signaling pathway in salivary adenoid cystic carcinoma. Ann Diagn Pathol 2014; 18: 10-13.
37. Bouaichi A, Aimad-Eddine S, Mommers XA, Ella B, Zwetyenga N,. Intra-mandibular adenoid cystic carcinoma. Rev Stomatol Chir Maxillofac Chir Orale 2014; 115: 100-104.
38. Dodd RL, Slevin NJ,. Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies. Oral Oncol 2006; 42: 759-769.
39. Bradley PJ,. Adenoid cystic carcinoma of the head and neck: A review. Curr Opin Otolaryngol Head Neck Surg 2004; 12: 127-132.
40. Kazumoto K, Hayase N, Kurosumi M, Kishi K, Uki J, Takeda F,. Multiple brain metastases from adenoid cystic carcinoma of the parotid gland. Case report and review of the literature. Surg Neurol 1998; 50: 475-479.
41. Amit M, Binenbaum Y, Trejo-Leider L, et al., International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck 2014. [Epub ahead of print].
42. Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ,. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995; 32: 619-626.
43. Oplatek A, Ozer E, Agrawal A, Bapna S, Schuller DE,. Patterns of recurrence and survival of head and neck adenoid cystic carcinoma after definitive resection. Laryngoscope 2010; 120: 65-70.
44. Spiro RH,. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 1997; 174: 495-498.
45. Fordice J, Kershaw C, El-Naggar A, Goepfert H,. Adenoid cystic carcinoma of the head and neck: Predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 1999; 125: 149-152.
46. Hammoud MA, Hassenbusch SJ, Fuller GN, Shi W, Leeds NE,. Multiple brain metastases: A rare manifestation of adenoid cystic carcinoma of the parotid gland. J Neurooncol 1996; 27: 61-64.
47. Sur RK, Donde B, Levin V, et al., Adenoid cystic carcinoma of the salivary glands: A review of 10 years. Laryngoscope 1997; 107: 1276-1280.
48. Kim M, Lee DW, Im J, et al., Adenoid cystic carcinoma of the breast: A case series of six patients and literature review. Cancer Res Treat 2014; 46: 93-97.
49. Ciccolallo L, Licitra L, Cantú G, Gatta G,; EUROCARE Working Group. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol 2009; 45: 669-674.
50. Chen AM, Bucci MK, Weinberg V, et al., Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: Prognostic features of recurrence. Int J Radiat Oncol Biol Phys 2006; 66: 152-159.
51. Balamucki CJ, Amdur RJ, Werning JW, et al., Adenoid cystic carcinoma of the head and neck. Am J Otolaryngol 2012; 33: 510-518.
52. Gomez DR, Hoppe BS, Wolden SL, et al., Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: A recent experience. Int J Radiat Oncol Biol Phys 2008; 70: 1365-1372.
53. Miglianico L, Eschwege F, Marandas P, Wibault P,. Cervico-facial adenoid cystic carcinoma: Study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13: 673-678.
54. Simpson JR, Thawley SE, Matsuba HM,. Adenoid cystic salivary gland carcinoma: Treatment with irradiation and surgery. Radiology 1984; 151: 509-512.
55. National Comprehensive Cancer Network. Head and neck cancer (version 2.2014). 2014. Available at: Www.nccn.org. Accessed June 30, 2014.
56. Vikram B, Strong EW, Shah JP, Spiro RH,. Radiation therapy in adenoid-cystic carcinoma. Int J Radiat Oncol Biol Phys 1984; 10: 221-223.
57. Huber PE, Debus J, Latz D, et al., Radiotherapy for advanced adenoid cystic carcinoma: Neutrons, photons or mixed beam? Radiother Oncol 2001; 59: 161-167.
58. Münter MW, Schulz-Ertner D, Hof H, et al., Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: Initial clinical results and toxicity of treatment. Radiat Oncol 2006; 1: 17.
59. Stannard C, Vernimmen F, Carrara H, et al., Malignant salivary gland tumours: Can fast neutron therapy results point the way to carbon ion therapy? Radiother Oncol 2013; 109: 262-268.
60. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG,. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review. Lancet Oncol 2011; 12: 815-824.
61. Schramm VL Jr, Srodes C, Myers EN,. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 1981; 107: 739-741.
62. de Haan LD, De Mulder PH, Vermorken JB, Schornagel JH, Vermey A, Verweij J,. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 1992; 14: 273-277.
63. Licitra L, Marchini S, Spinazzè S, et al., Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991; 68: 1874-1877.
64. Cerda T, Sun XS, Vignot S, et al., A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). Crit Rev Oncol Hematol 2014; 91: 142-158.
65. Locati LD, Perrone F, Losa M, et al., Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 2009; 45: 986-990.
66. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr,. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999; 12: 956-960.
67. Ghosal N, Mais K, Shenjere P, et al., Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg 2011; 49: 510-515.
68. Duffaud F, Le Cesne A,. Imatinib in the treatment of solid tumours. Target Oncol 2009; 4: 45-56.
69. Hotte SJ, Winquist EW, Lamont E, et al., Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23: 585-590.
70. Jakob JA, Kies MS, Glisson BS, et al., A phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck 2014. [Epub ahead of print].
71. Locati LD, Bossi P, Perrone F, et al., Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol 2009; 45: 574-578.
72. Hitre E, Budai B, Takácsi-Nagy Z, et al., Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: A phase II trial. Br J Cancer 2013; 109: 1117-1122.
73. Agulnik M, Cohen EW, Cohen RB, et al., Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25: 3978-3984.
74. Hao L, Xiao-lin N, Qi C, Yi-ping Y, Jia-quan L, Yan-ning L,. Nerve growth factor and vascular endothelial growth factor: Retrospective analysis of 63 patients with salivary adenoid cystic carcinoma. Int J Oral Sci 2010; 2: 35-44.
75. Chau NG, Hotte SJ, Chen EX, et al., A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: Current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 2012; 23: 1562-1570.
76. Rugo HS, Herbst RS, Liu G, et al., Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474-5483.
77. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G,. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009; 106: 18740-18744.
78. Argiris A, Burtness B, Axelrod RS, Deconti RC, Forastiere AA,. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011; 117: 3374-3382.
79. Dubbelman AC, Upthagrove A, Beijnen JH, et al., Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; 70: 653-663.
80. Dillon P, Moskaluk CA, Petroni G, et al., Phase II study of dovitinib (TKI258) in patients with progressive metastatic adenoid cystic carcinoma. J Clin Oncol 2013; 31 (suppl):abstract 6021.
81. Goncalves P, Kummar S, Siu LL, et al., A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC). J Clin Oncol 2013; 31(suppl): Abstract 6045.
82. Hoover AC, Milhem MM, Anderson CM, et al., Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial. Head Neck 2014. [Epub ahead of print].